ATIBAR - efficacy and safety of two doses of allert in patients allergic to birch pollen

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
A multicentre, Double-blind, Placebo-Controlled, Randomized Trial to Assess the Efficacy and Tolerability of Two Dosing Regimens of AllerT, a Combination of Contiguous Overlapping Peptides Derived from Bet v 1, in Adults with Birch Pollen Allergic Rhinitis/Rhinoconjunctivitis
Epistemonikos ID: 6178d25ed6059bf6ae357b56a4464feb0dd9c05a
First added on: May 17, 2024